# Nuclide record paper-netter-1-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-netter-1-nejm-2017" ;
  schema:name "NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide"@en ;
  schema:description "Radioligand therapy with lutetium-177 dotatate reduced the risk of progression or death by nearly 80 percent compared with high-dose octreotide in midgut neuroendocrine tumours, the first randomised proof that targeted radiation works in these cancers."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1607427>, <https://pubmed.ncbi.nlm.nih.gov/28076709/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1607427> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Strosberg J, El-Haddad G, Wolin E, et al." ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/small-intestinal-net/> ;
  nuclide:trials <https://nuclide.cc/trials/netter-1/> ;
  nuclide:journals <https://nuclide.cc/journals/nejm/> .